Neuropharma Introduces in Clinical Trials its First Medicine for the Treatment of Alzheimer's
Madrid, Spain (ots/PRNewswire) - - Preliminary Tests Demonstrate That the NP031112 Molecule has a Very Innovative Therapeutic Potential - Phase I Will Consist of Two Stages: in the First One the Drug Will be Administrated in Scalating Single Doses, and in the Second One, in a Repeated Dose for Seven Days. Neuropharma, a subsidiary of the Zeltia Group ...
mehr